Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNX NASDAQ:EMBC NASDAQ:NNOX NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$20.49+1.4%$18.94$8.89▼$26.66$890.70MN/A601,493 shs581,308 shsEMBCEmbecta$14.26-3.1%$13.47$9.20▼$21.48$834.07M1.11591,002 shs321,823 shsNNOXNano-X Imaging$3.79+2.7%$4.19$3.60▼$11.00$218.99M1.891.68 million shs1.31 million shsTNDMTandem Diabetes Care$13.11+5.6%$12.73$9.98▼$42.70$885.84M1.481.74 million shs2.43 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics+1.71%-11.09%+7.27%+49.48%+2,020,999,900.00%EMBCEmbecta+4.25%+0.75%+1.59%+42.54%+4.25%NNOXNano-X Imaging-0.27%-6.82%-4.65%-30.05%-37.56%TNDMTandem Diabetes Care+2.22%-1.82%-0.80%-27.27%-69.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$20.49+1.4%$18.94$8.89▼$26.66$890.70MN/A601,493 shs581,308 shsEMBCEmbecta$14.26-3.1%$13.47$9.20▼$21.48$834.07M1.11591,002 shs321,823 shsNNOXNano-X Imaging$3.79+2.7%$4.19$3.60▼$11.00$218.99M1.891.68 million shs1.31 million shsTNDMTandem Diabetes Care$13.11+5.6%$12.73$9.98▼$42.70$885.84M1.481.74 million shs2.43 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics+1.71%-11.09%+7.27%+49.48%+2,020,999,900.00%EMBCEmbecta+4.25%+0.75%+1.59%+42.54%+4.25%NNOXNano-X Imaging-0.27%-6.82%-4.65%-30.05%-37.56%TNDMTandem Diabetes Care+2.22%-1.82%-0.80%-27.27%-69.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.83Moderate Buy$24.4419.30% UpsideEMBCEmbecta 2.75Moderate Buy$19.0033.24% UpsideNNOXNano-X Imaging 3.50Strong Buy$8.50124.27% UpsideTNDMTandem Diabetes Care 2.31Hold$22.4471.15% UpsideCurrent Analyst Ratings BreakdownLatest NNOX, BBNX, EMBC, and TNDM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/1/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Buy$18.00 ➝ $26.0010/1/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$18.00 ➝ $26.009/29/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.009/22/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $28.009/19/2025NNOXNano-X ImagingD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/8/2025TNDMTandem Diabetes CareOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$44.00 ➝ $22.009/5/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/26/2025EMBCEmbectaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/21/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$10.35 ➝ $11.008/13/2025NNOXNano-X ImagingD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.008/11/2025NNOXNano-X ImagingAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 10/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$65.12M13.68N/AN/A($5.72) per share-3.58EMBCEmbecta$1.12B0.74$3.37 per share4.23($12.80) per share-1.11NNOXNano-X Imaging$11.28M19.41N/AN/A$3.27 per share1.16TNDMTandem Diabetes Care$940.20M0.94N/AN/A$4.01 per share3.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/AEMBCEmbecta$78.30M$1.439.974.640.787.58%-23.40%14.46%11/25/2025 (Estimated)NNOXNano-X Imaging-$53.52M-$0.90N/AN/AN/A-468.29%-32.09%-28.73%11/20/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/5/2025 (Estimated)Latest NNOX, BBNX, EMBC, and TNDM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025NNOXNano-X Imaging-$0.15-$0.23-$0.08-$0.23$3.20 million$3.04 million8/8/2025Q3 2025EMBCEmbecta$0.7720$1.12+$0.3480$0.78$278.15 million$295.50 million8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AEMBCEmbecta$0.604.21%N/A41.96%N/ANNOXNano-X ImagingN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ALatest NNOX, BBNX, EMBC, and TNDM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/6/2025EMBCEmbectaquarterly$0.154.14%8/29/20258/29/20259/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A14.6813.79EMBCEmbectaN/A2.471.78NNOXNano-X ImagingN/A4.194.03TNDMTandem Diabetes Care2.322.441.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AEMBCEmbecta93.83%NNOXNano-X Imaging21.49%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AEMBCEmbecta0.42%NNOXNano-X Imaging7.74%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.47 millionN/AN/AEMBCEmbecta2,10058.49 million58.24 millionOptionableNNOXNano-X Imaging19057.78 million53.31 millionOptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableNNOX, BBNX, EMBC, and TNDM HeadlinesRecent News About These Companiesagilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know2 hours ago | msn.comTandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 20253 hours ago | businesswire.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmOctober 1 at 12:00 PM | globenewswire.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 30 at 4:45 PM | globenewswire.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzSeptember 30 at 3:00 PM | globenewswire.comCanaccord Genuity Maintains Tandem Diabetes Care (TNDM) Buy RecommendationSeptember 30 at 5:46 AM | msn.comCanaccord Genuity Group Reiterates Buy Rating for Tandem Diabetes Care (NASDAQ:TNDM)September 30 at 2:42 AM | americanbankingnews.comTandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United StatesSeptember 29 at 7:45 PM | finance.yahoo.comTandem Diabetes Care (NASDAQ:TNDM) Earns Buy Rating from Canaccord Genuity GroupSeptember 29 at 10:29 AM | marketbeat.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDMSeptember 28, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDMSeptember 28, 2025 | prnewswire.comAssenagon Asset Management S.A. Buys New Shares in Tandem Diabetes Care, Inc. $TNDMSeptember 28, 2025 | marketbeat.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 27, 2025 | globenewswire.comBanque Pictet & Cie SA Buys Shares of 84,028 Tandem Diabetes Care, Inc. $TNDMSeptember 27, 2025 | marketbeat.comWhy Tandem Diabetes (TNDM) Shares Are Trading Lower TodaySeptember 25, 2025 | msn.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 24, 2025 | globenewswire.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDMSeptember 23, 2025 | prnewswire.comTNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law FirmSeptember 21, 2025 | businesswire.comTandem Diabetes Care, Inc. $TNDM Shares Acquired by Voya Investment Management LLCSeptember 21, 2025 | marketbeat.comLevi & Korsinsky Launches Fraud Investigation on Behalf of Tandem Diabetes Care, Inc. (TNDM) ShareholdersSeptember 21, 2025 | barrons.comLevi & Korsinsky Investigates Tandem Diabetes Care, Inc. (TNDM) Over Potential Securities Fraud AllegationsSeptember 20, 2025 | cantechletter.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNNOX, BBNX, EMBC, and TNDM Company DescriptionsBeta Bionics NASDAQ:BBNX$20.49 +0.28 (+1.39%) As of 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Embecta NASDAQ:EMBC$14.26 -0.45 (-3.06%) Closing price 04:00 PM EasternExtended Trading$14.08 -0.17 (-1.23%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Nano-X Imaging NASDAQ:NNOX$3.79 +0.10 (+2.71%) Closing price 04:00 PM EasternExtended Trading$3.80 +0.00 (+0.13%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.Tandem Diabetes Care NASDAQ:TNDM$13.11 +0.70 (+5.64%) Closing price 04:00 PM EasternExtended Trading$13.03 -0.08 (-0.61%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry Rocket Lab's Electron: The Quiet Workhorse Powering Momentum CoreWeave: Why the New King of AI Infrastructure Has Room to Run Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
